NCT02617810View on ClinicalTrials.gov

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Healthy
Interventions
DRUG

JNJ-42847922

Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.

DRUG

Midazolam

Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.

DRUG

Warfarin

Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.

Trial Locations (1)

Unknown

Overland Park

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02617810 - A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants | Biotech Hunter | Biotech Hunter